Pyxis Oncology (PYXS)
NASDAQ:PYXS
Want to see PYXS full AI Analyst Report?
Pembrolizumab, Pyx-201
Advanced Solid Tumours
Phase I/II
Recruiting
Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Jan 22, 2025
―
Pyx-201
Advanced Solid Tumor, Solid Tumor
Phase I
Recruiting
Study of PYX-201 in Solid Tumors
Jan 30, 2023
―
Pyx-106
Solid Tumor
Phase I
Active Not Recruiting
Study of PYX-106 in Solid Tumors
Jan 30, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Pyxis Oncology (PYXS) have in its pipeline
PYXS is currently developing the following drugs: Pembrolizumab, Pyx-201, Pyx-201, Pyx-106. These drug candidates are in various stages of clinical development as the company works toward FDA approval.